The INTERCEPT-T2D project is a unique opportunity to improve diabetes recommendations

Explore how the research project will progress over five years, and the outcomes and impacts that are anticipated

Europe’s diabetes pandemic is growing rapidly enough to challenge our health services and gradually enough to alert the European community about the need of progress in diabetes research, prevention and treatment to cope with its rising burden. The scale of the problem demands a complete rethinking of how we manage diabetes.
Currently, there are no recommendations considering the inflammatory and immune status of diabetic citizens while it is well accepted that chronic inflammation is a key parameter involved in T2D switch from asymptomatic to symptomatic complicated T2D.

The INTERCEPT-T2D project is a unique opportunity to improve diabetes recommendations by considering immune and inflammatory biomarkers at diagnosis and to propose a tailored medicine to tackle diabetes comorbidities and vascular complication.

research-project
Expected Results

Expected Results

  • Demonstration of a causal link between inflammasome mediated-diabetic dysimmunity and a specific trajectory towards symptomatic T2D
  • Definition of immune parameters related to this dysimmune-T2D to identify the citizens at risk of diabetes complications
  • Complete characterization of a novel endotype of T2D: Inflammatory mediated-T2D
  • Completion of a randomized, double-blind, placebocontrolled multicentre Trial (Dapansutrile in Diabetes and Complications)
  • Awareness and knowledge on the aetiology of dysimmunity in diabetes triggering the transition from diagnosis to complications

The specific needs

The specific needs

Europe’s diabetes pandemic is growing, both in terms of patient care and economic burden on patients, their families, and the healthcare system: need for prevention and early interventions

  • Currently, the management of T2D at diagnosis is driven by lowering the blood glucose but not preventing the disease transition towards symptomatic disease. Need for stratified precision medicine
  • To date, there are no recommendations considering the inflammatory and immune status of the diabetic citizens while it is well accepted that chronic inflammation is a key parameter involved in T2D switch from asymptomatic to symptomatic T2D: need to revise current T2D classifications by considering chronic inflammatory and immune markers
  • Need to understand the biology underlying this dysimmune diabetes

hope-achieve

What does INTECEPT-T2D hope to achieve

Definition of an inflammatory score associated to immune-dependent T2D that includes biological and clinical parameters ready for use routinely in the clinic, to improve the diagnosis of diabetes and monitoring its evolution towards complications

  • Validation of the clinical superiority of OLT1177 (NLRP3 inflammasome inhibitor Dapansutrile) as add-on therapy
  • Recommendations (in compliance and agreement with European and International Diabetes Associations) for personalised strategies to intercept NLRP3 inflammasome-dependent inflammatory transition and tackle diabetic complications

impact

Impact

Increased life expectancy and improved quality of life for T2D patients treated with NLRP3 inhibitor

  • Reduced burden of diabetes for the health system
  • Patient empowerment: dissemination of the project results via patient associations and other media will allow patients and clinicians to make a joint and informed decision on the most appropriate treatment to control T2D evolution
  • Within 3 years after the end of the project, a new and efficient anti-inflammatory therapy to better manage T2D into the market
  • Extension of our results to common chronic inflammatory diseases. This will be facilitated by collaborations with other EU projects financed under this topic.